SARS-CoV-2 reinfection and implications for vaccine development

Hum Vaccin Immunother. 2020 Dec 1;16(12):3061-3073. doi: 10.1080/21645515.2020.1830683.

Abstract

Coronavirus disease 2019 (COVID-19) pandemic continues to constitute a public health emergency of international concern. Multiple vaccine candidates for COVID-19, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have entered clinical trials. However, some evidence suggests that patients who have recovered from COVID-19 can be reinfected. For example, in China, two discharged COVID-19 patients who had recovered and fulfilled the discharge criteria for COVID-19 were retested positive to a reverse transcription polymerase chain reaction (RT-PCR) assay for the virus. This finding is critical and could hamper COVID-19 vaccine development. This review offers literature-based evidence of reinfection with SARS-CoV-2, provides explanation for the possibility of SARS-CoV-2 reinfection both from the agent and host points of view, and discusses its implication for COVID-19 vaccine development.

Keywords: SARS-CoV-2; covid-19; reactivation; reinfection; vaccine.

Publication types

  • Review

MeSH terms

  • Animals
  • COVID-19 / epidemiology
  • COVID-19 / immunology
  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / administration & dosage*
  • COVID-19 Vaccines / immunology
  • Drug Development / methods
  • Drug Development / trends*
  • Humans
  • Reinfection / epidemiology
  • Reinfection / immunology
  • Reinfection / prevention & control*
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / immunology

Substances

  • COVID-19 Vaccines

Grants and funding

This review received no external funding.